Kenvue Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Kenvue Bundle
See the Bigger Picture
Curious where Kenvue’s products sit — Stars, Cash Cows, Dogs or Question Marks? This snapshot hints at positioning, but the full BCG Matrix gives quadrant-by-quadrant clarity, data-backed recommendations, and a ready-to-use strategy. Purchase the complete report to cut through the noise and start making smarter investment and product decisions today.
Stars
Listerine
Listerine sits in a growing global mouthwash market estimated at about $6.7 billion in 2024 with a ~5% CAGR as premiumization and rinse adoption rise in emerging markets. Listerine offers category leadership with a ≈35% global share and strong dental professional endorsements. Maintain heavy media, sampling and dentist partnerships to defend share while the market expands. Rapidly scale innovations in gum health and sensitivity to capture premium growth.
Neutrogena
Neutrogena is a Stars asset for Kenvue, delivering roughly 20% of Kenvue’s 2024 net sales—about $2.7B of ~$13.5B—driven by derm‑backed facial care, sun protection and derm‑beauty crossovers. The brand holds high share in key mass and drug channels with a strong science narrative and clinical claims that support premium pricing. Prioritize investment in hero SKUs, clinical studies and DTC content to convert younger shoppers. Win in retail endcaps and social‑led launch cycles to sustain growth.
Aveeno
Aveeno, Kenvue’s sensitive-skin authority, benefits from the skin-barrier and natural-leaning trends and shows strong momentum in eczema relief and gentle body care. Maintain elevated R&D and HCP advocacy while expanding into derm-problem and OTC-adjacent sets. Prioritize refillable formats and credible eco cues only where retail velocity proves impact. Leverage clinical positioning to defend premium pricing and channel growth.
Zyrtec
Zyrtec remains a Stars-position brand for Kenvue: allergy is a resilient, seasonally spiky category and Zyrtec's multi-decade recognition drives high repeat usage and strong retail velocity; 2024 retail sales exceeded $1B globally, supporting continued investment in always-on retail presence and weather-triggered digital peaks.
- Maintain always-on retail distribution
- Deploy weather-triggered digital media
- Selective line-extensions: kids, dissolvables
- Defend versus flankers via premium SKUs
Tear-free Baby Cleansing (Johnson’s)
Tear-free Baby Cleansing (Johnson’s) is a Stars BCG position as the baby wash/shampoo line is regaining trust through gentler, simpler formulas and expanded parent education efforts in 2024, with momentum in select markets and online gifting kits driving share gains. Focus: double down on pediatrician endorsements and subscription bundles while localizing fragrances and formats without overcomplicating SKUs.
- Pediatrician endorsements—priority
- Subscription bundles + gifting kits—scale online
- Localized fragrances/formats—limit SKU complexity
Oral-care crowns a $6.7B market as skin and allergy lines reach billion-dollar scale
Stars: Listerine leads a $6.7B mouthwash market (2024) at ≈35% share; Neutrogena ~ $2.7B (≈20% of Kenvue’s $13.5B 2024 sales); Aveeno strong in sensitive skin/eczema; Zyrtec >$1B retail sales (2024); Johnson’s baby wash regaining share via pediatric endorsements.
| Brand | 2024 | Notes |
|---|---|---|
| Listerine | $6.7B market, ≈35% share | Premiumization, 5% CAGR |
| Neutrogena | $2.7B | 20% of Kenvue sales |
| Zyrtec | >$1B | Seasonal peaks |
What is included in the product
Detailed Word Document
In-depth BCG review of Kenvue products with strategic moves for Stars, Cash Cows, Question Marks and Dogs - invest, hold or divest.
Customizable Excel Spreadsheet
Clean, distraction-free Kenvue BCG Matrix condenses portfolios into one-page quadrants for swift C‑level decisions.
Cash Cows
Tylenol
Tylenol sits as a classic cash cow: core analgesic with massive household penetration in a mature category, delivering reliable velocity, strong gross margins and low relative promotional need. Protecting shelf space and flawless supply are priority operational levers; keep dosing education clear to sustain trust and reduce liability. Milk steady cash flows and trial premium packs only in markets where observed price elasticity supports uppricing.
Motrin
Motrin is an established ibuprofen franchise dating to 1974 with strong repeat purchasers and high brand trust, positioned as a cash cow within Kenvue’s pain portfolio. Category growth is modest, supporting steady cash flow while efficient trade spend and clear OTC claims limit private-label erosion. Focus on pack-size optimization and club-format SKUs to boost gross margins and working-capital conversion in core markets.
Band-Aid
Band-Aid, owned by Kenvue (the consumer-health company spun out of Johnson & Johnson in 2023), is an iconic first-aid leader in a stable, habitual market. High brand default at shelf and wide distribution support steady cash flow; refresh designs and kid licenses sparingly to sustain relevance. Use Kenvue's scale to secure premium placement and minimize promotional depth to protect margins.
Neosporin
Neosporin, under Kenvue (spun off from Johnson & Johnson in 2023), functions as a Cash Cow: antibiotic ointments see steady, need-driven purchases with low innovation burden and durable brand recall, enabling stable OTC margins and predictable cash generation.
- Keep education simple: wound healing steps
- Promote combo value packs
- Differentiate vs store brands with clear functional claims
Lip & Body Lotions (core lines)
Lip and body lotions (core lines) are mature body-care staples for Kenvue, delivering consistent unit turns and predictable seasonal patterns that support stable cash generation.
These SKUs are margin-friendly when sourced and packed efficiently, so priority is on supply-chain optimization and mix management rather than heavy media spending.
Use seasonal multi-packs and bundle promotions to smooth demand peaks and reduce stockouts, preserving shelf velocity and unit economics.
- Focus: supply-chain & mix management
- Channel: low-media, trade/promotions
- Tactic: seasonal multi-packs to smooth demand
- Benefit: predictable turns, margin resilience
Defend OTC margins: shelf, supply and pack/mix protect cash-cow profits
Tylenol, Motrin, Band‑Aid and Neosporin are Kenvue cash cows delivering steady OTC cash flow with low promo intensity and high household penetration; prioritize shelf, supply and pack/mix to protect margins. 2024 saw Kenvue net sales of 12.9 billion USD, with cash‑cow categories contributing ~60% of OTC operating profit; focus on margin-preserving SKUs and seasonal bundles.
| Metric | 2024 |
|---|---|
| Kenvue net sales | 12.9B USD |
| Cash-cow OP contribution | ~60% |
What You See Is What You Get
Kenvue BCG Matrix
The Kenvue BCG Matrix you're previewing is the exact file you'll receive after purchase. No watermarks, no placeholder content—just a fully formatted, ready-to-use strategic report. Designed by strategy experts, it's editable and presentation-ready for your team or investors. Buy once and download immediately; what you see is precisely what lands in your inbox.
Dogs
Clean & Clear
Clean & Clear, a legacy teen acne brand from the J&J lineage now in Kenvue, is being squeezed by derm-clinic labels and fast-growing indie players; it holds low share in core U.S. and EU teen skincare segments. Industry data shows acne treatment/category growth is modest, ~4% CAGR (2024–29), limiting upside for heavy investment. With slow-to-no growth in key markets and constrained ROI, pruning SKUs or licensing the brand out warrants serious consideration.
Long-tail Regional OTC SKUs
Long-tail regional OTC SKUs—niche pain/cold remedies with limited geography and weak awareness—often follow an 80/20 pattern: roughly 30% of SKUs can contribute under 5% of sales, while tying up working capital and incurring shelf fees with little pull. Rationalize or exit non-velocity codes, retaining only top-performing SKUs to improve turns. Reallocating inventory spend toward digital-first winners can unlock cash and margin to fund growth.
Older Baby Accessories
Older Baby Accessories sit in Dogs: non-core combs, kits and gadgets deliver low margin with little brand leverage and face a fragmented, commoditized market where private-label penetration exceeds 30% in key markets (2024). Trim the tail, redirect R&D and shelf space to wash and skin care where Kenvue brand equity drives premium placement and higher margins. Pursue divestment if credible buyers emerge to reallocate capital to core growth segments.
Legacy Mouth Fresheners
Dogs: Legacy Mouth Fresheners sit as low-growth, low-share sideline in Kenvue’s oral-care portfolio; the global oral-care market was about $44.9B in 2024, but mouth-freshener subsegments show low single-digit growth and limited differentiation. Private-label penetration (~10% in US oral care) keeps price pressure high, so sunset quietly and reallocate capex and marketing to therapeutic rinses; avoid distraction.
- Category: Dogs
- Market size: $44.9B (2024)
- Private-label pressure: ~10%
- Action: Sunset, reallocate to therapeutics
Underperforming Sun Sub-lines
Underperforming Sun sub-lines sit in the Dogs quadrant after 2024 saw new-launch momentum shift to mineral and dermatologist-led formats, leaving legacy SPF formats with declining velocity and rising inventory days. Shelf presence without consumer pull has become a cash trap; delist laggards and concentrate on hero SKUs that sustain proven sell-through. Recycle weak claims into stronger franchises focused on mineral, sensitive-skin and dermatologist-endorsed positioning.
Prune legacy SKUs, reallocate to derm-led and mineral sun winners
Dogs: low-share, low-growth legacy SKUs (Clean & Clear teen acne, older baby accessories, mouth fresheners, underperforming sun lines) tie up inventory and margin; core markets show ~4% acne CAGR (2024–29) and global oral-care $44.9B (2024) with ~10% private-label pressure. Prune tails, license or divest, reallocate capex/marketing to high-velocity derm-led and sun mineral heroes.
| Category | 2024 Market | Share | Growth | Action |
|---|---|---|---|---|
| Acne (Clean & Clear) | — | Low | ~4% CAGR | License/prune |
| Oral: mouth fresheners | $44.9B | Low | Low single digits | Sunset |
Question Marks
Derm Sunscreen Revamps
Derm Sunscreen Revamps sit in high-growth sun care pockets — mineral SPF segment grew ~12% in 2024 and daily/sensitive subsegments outpaced category averages — yet these niches are crowded with legacy and indie rivals, leaving Kenvue with low share in some retail and digital channels. Heavy investment in claim validation and UGC-driven social proof can rapidly convert trial into share; if early KPIs (trial, repeat) lag after 6–9 months, cut fast to reallocate spend.
Oral Care Devices & Advanced Rinses
Oral Care Devices & Advanced Rinses sit as Question Marks: the global mouthwash market is about $7B in 2024 and electric toothbrushes near $4B, with Listerine holding roughly 30% share in many markets, showing adjacency and tech-led whitening/gum-health upsides. Category growth is real but share is not guaranteed; success requires dentist endorsement, consumer education and disciplined premium pricing. Pilot big in key test markets, then scale rapidly or shelve.
Women’s Intimate & pH-care Expansions
Rising consumer demand for gentle, OB-GYN‑recommended pH‑balanced routines is driving a sector growing at an estimated 5–7% CAGR through 2028 (2024 market reports), yet Kenvue—with roughly $13.4bn in 2023 consumer health revenue—still holds limited share in intimate/pH care subsegments. Rapid rollout of clinical claims, published trials and retail education are required to convert trial into share. Kenvue should invest aggressively or form strategic partnerships rather than test-the-waters.
Sleep & Stress OTC Adjacent
Sleep & Stress OTC Adjacent sits as a Question Mark: consumer demand for sleep and stress relief surged post‑pandemic with WHO and national surveys showing persistent sleep deficits, but brand permission must be earned through clinical credibility. Early pilots can burn cash before traction; if concept tests clear, prioritize clear safety and dosing guidance and robust adverse‑event monitoring. If not scalable, prefer licensing or divestment to protect margins and R&D runway.
- Market signal: sustained consumer interest in sleep/stress remedies
- Risk: high pilot burn with uncertain repeat purchase
- Go/no‑go: proceed only after positive concept and safety data
- Exit: license or walk if metrics fail
Baby Naturals & Subscription Bundles
Question Marks: Baby Naturals & Subscription Bundles face fierce online competition despite parents prioritizing clean formulas and predictable replenishment; 2024 e-commerce penetration in baby care is ~30%, share is patchy and loyalty fragile. Differentiate via pediatrician-led content and skin science; if projected LTV fails sensitivity tests, plan a rapid exit.
- Prioritize pediatrician-led content
- Measure LTV/CAC monthly
- Exit if LTV < 1.2 within 12 months
Niche plays: derm +12%, oral $4B/$7B, test trial→repeat
Question Marks: Derm sunscreen niches grew ~12% in 2024 but Kenvue holds low share; oral care devices/mouthwash markets ~$4B/$7B (2024) with Listerine ~30% share; baby naturals e‑commerce ~30% penetration (2024) and Kenvue share patchy; sleep/stress pilots need safety proof before scale. Measure trial, repeat, LTV/CAC; scale fast or exit.
| Segment | 2024 market | Kenvue share | Key KPI | Go/no‑go |
|---|---|---|---|---|
| Derm sunscreen | mineral +12% growth | low | trial→repeat | 6–9m |
| Oral care | $4B/$7B | adjacent | dentist uptake | pilot→scale |
| Baby naturals | e‑comm 30% | patchy | LTV/CAC | exit if LTV<1.2 |
| Sleep/stress | growing post‑pandemic | none/limited | safety trials | license if fail |